Download PDF
Horm Metab Res 2014; 46(07): 510-514
DOI: 10.1055/s-0034-1371823
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Hageman Factor C46T Promoter Gene Polymorphism in Patients with Hypercortisolism

R. Świątkowska-Stodulska
1   Department of Endocrinology and Internal Medicine, Medical University of Gdańsk, Gdańsk, Poland
,
A. Kitowska
2   Department of Molecular Medicine, Medical University of Gdansk, Gdańsk, Poland
,
A. Skibowska-Bielińska
3   General Clinical Laboratory, Clinical University Centre, Gdańsk, Poland
,
P. Wiśniewski
1   Department of Endocrinology and Internal Medicine, Medical University of Gdańsk, Gdańsk, Poland
,
K. Sworczak
1   Department of Endocrinology and Internal Medicine, Medical University of Gdańsk, Gdańsk, Poland
› Author Affiliations
Further Information

Publication History

received 05 November 2013

accepted 24 February 2014

Publication Date:
01 April 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Glucocorticoids are a group of hormones with a particularly significant effect on hemostasis. In hypercortisolemic patients increased concentrations of II, VIII, and von Willebrand factors were reported. Considerably fewer studies were concerned with factor XII (FXII). There are reports of decreased FXII concentrations in both venous and arterial thrombosis patients. Also, it was determined that FXII C46T promoter gene polymorphism leads to changes of its concentration. The aim of the study was to determine the C46T polymorphism of FXII promoter gene in hypercortisolemic patients. Thirty hypercortisolemic patients were enrolled in the study. Twenty-nine healthy individuals served as controls. Genomic DNA was isolated from peripheral blood leukocytes. To analyse the polymorphism, PCR products were digested by Hga I at 37°C for 23 h, subjected to 2% agarose gel, and stained with ethidium bromide. In all subjects FXII activity was determined using a clot-based method. All statistical calculations were performed using STATA 12.0 software. A p-value lower than 0.05 was considered statistically significant. Prevalence of FXII C46T polymorphism did not differ significantly between hypercortisolemic patients and controls. No correlation was found between FXII activity and its gene promoter polymorphism in the hypercortisolemic group; however, a clear trend was recorded toward higher FXII activities in 46C homozygotes, and lower in 46T homozygotes. Mean FXII activities did not differ significantly between hypercortisolemic patients and the control group. It seems that in hypercortisolemic patients no significant disorders are present concerning FXII concentrations due to the C46T polymorphism of its gene promoter.

Key words

coagulation factor XII - Cushing’s syndrome - subclinical Cushing’s syndrome
 

  • References

  • 1 Świątkowska-Stodulska R, Babińska A, Sworczak K. Effect of selected hormones on particular parameters of hemostasis. Wiad Lek 2007; 60: 390-393 [Polish]
    PubMedGoogle Scholar
  • 2 Świątkowska-Stodulska R, Babińska A, Sworczak K. Hypercortisolemia and hemostasis. Pol Merk Lek 2009; 152: 142-144 [Polish]
    PubMedGoogle Scholar
  • 3 van der Pas R, Leebeek FW, Hofland LJ, de Herder WW, Feelders RA. Hypercoagulability in Cushing’s syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf) 2013; 78: 481-488
    CrossrefPubMedGoogle Scholar
  • 4 Small M, Lowe GD, Forbes CD, Thomson JA. Thromboembolic complications in Cushing’s syndrome. Clin Endocrinol (Oxf) 1983; 19: 503-511
    CrossrefPubMedGoogle Scholar
  • 5 Brotman DJ, Girod JP, Posch A, Jani JT, Patel JV, Gupta M, Lip GY, Reddy S, Kickler TS. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res 2006; 118: 247-252
    CrossrefPubMedGoogle Scholar
  • 6 Casonato A, Pontara E, Boscaro M, Sonino N, Sartorello F, Ferasin S, Girolami A. Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing’s syndrome. Blood Coagul Fibrinol 1999; 10: 145-151
    CrossrefPubMedGoogle Scholar
  • 7 Dal Bo Zanon R, Fornasiero L, Boscaro M, Cappellato G, Fabris F, Girolami A. Increased factor VIII associated activities in Cushing’s syndrome: a propable hypercoagulable state. Thromb Haemost 1982; 47: 116-117
    PubMedGoogle Scholar
  • 8 Ikkala E, Myllyla G, Pelkonen R, Rasi V, Viinikka L, Ylikorkala O. Haemostatic parameters in Cushing’s syndrome. Acta Med Scand 1985; 217: 507-511
    PubMedGoogle Scholar
  • 9 Jacoby RC, Owings JT, Ortega T, Gosselin R, Feldman EC. Biochemical basis for the hypercoagulable state seen in Cushing syndrome. Arch Surg 2001; 136: 1003-1006
    CrossrefPubMedGoogle Scholar
  • 10 Patrassi GM, Dal Bo Zanon R, Boscaro M, Martinelli S, Girolami A. Further studies on the hypercoagulable state of patients with Cushing’s syndrome. Thromb Haemost 1985; 54: 518-520
    PubMedGoogle Scholar
  • 11 Patrassi GM, Sartori MT, Viero ML, Scarano L, Boscaro M, Girolami A. The fibrinolytic potential in patients with Cushing’s disease: a clue to their hypercoagulable state. Blood Coagul Fibrinol 1992; 3: 789-793
    CrossrefPubMedGoogle Scholar
  • 12 Rosenfeld BA, Faraday N, Campbell D, Dise K, Bell W, Goldschmidt P. Hemostatic effects of stress hormone infusion. Anesthesiology 1994; 81: 1116-1126
    CrossrefPubMedGoogle Scholar
  • 13 Kastelan D, Dusek T, Kraljevic I, Polasek O, Giljevic Z, Solak M, Salek SZ, Jelcic J, Aganovic I, Korsic M. Hypercoagulability in Cushing’s syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 2009; 36: 70-74
    CrossrefPubMedGoogle Scholar
  • 14 Halleux CM, Declerck PJ, Tran SL, Detry R, Brichard SM. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab 1999; 84: 4097-4105
    CrossrefPubMedGoogle Scholar
  • 15 Kastelan D, Dusek T, Kraljevict I, Aganovict I. Hypercoagulable state in Cushing’s syndrome in reversible following remission. Clin Endocrinol (Oxf) 2013; 78: 102-106
    CrossrefPubMedGoogle Scholar
  • 16 Stavrou E, Schimaier AH. Factor XII: What does it contribute to our understanding of the physiology and pathophysiology of hemostasis and thrombosis. Thromb Res 2010; 125: 210-215
    CrossrefPubMedGoogle Scholar
  • 17 Schmaier AH. The elusive physiologic role of factor XII. J Clin Invest 2008; 118: 3006-3009
    PubMedGoogle Scholar
  • 18 Renne T, Schmailer AH, Nickel KF, Blombak M, Maas C. In vivo roles of factor XII. Blood 2012; 120: 4296-4303
    CrossrefPubMedGoogle Scholar
  • 19 Renne T. The procoagulant and proinflammatory plasma contact system. Semin Immunophatol 2010; 34: 31-41
    PubMedGoogle Scholar
  • 20 Kuhli C, Scharrer I, Koch F, Ohrloff C, Hattenbach LO. Factor XII deficiency: a thrombophilic risk factor for retinal vein occlusion. Am J Ophthalmol 2004; 137: 459-464
    CrossrefPubMedGoogle Scholar
  • 21 Lessiani G, Falco A, Nicolucci E, Rolandi G, Davì G. Deep venous thrombosis and previous myocardial infarction in mild factor XII deficiency: a risk factor for both venous and arterial thrombosis. J Thromb Thrombolysis 2009; 27: 348-351
    CrossrefPubMedGoogle Scholar
  • 22 Pérez-Montes R, Sedano C, Yáñez L, Pérez-Puente A, Vallverdu H, Hernández JL, Iriondo A. Deep venous thrombosis, protein S deficiency and homozygous Factor XII 46T mutation. Eur J Pediatr 2005; 164: 591-593
    CrossrefPubMedGoogle Scholar
  • 23 Cochery-Nouvellon E, Mercier E, Lissalde-Lavigne G, Daurès JP, Quéré I, Dauzat M, Marès P, Gris JC. Homozygosity for the C46T polymorphism of the F12 gene is a risk factor for venous thrombosis during the first pregnancy. J Thromb Haemost 2007; 5: 700-707
    CrossrefPubMedGoogle Scholar
  • 24 Reuner KH, Jenetzky E, Aleu A, Litfin F, Mellado P, Kloss M, Jüttler E, Grau AJ, Rickmann H, Patscheke H, Lichy C. Factor XII C46T gene polymorphism and the risk of cerebral venous thrombosis. Neurology 2008; 70: 129-132
    PubMedGoogle Scholar
  • 25 Endler G, Mannhalter C, Sunder-Plassmann H, Lalouschek W, Kapiotis S, Exner M, Jordanova N, Meier S, Kunze F, Wagner O, Huber K. Homozygosity for the C→T polymorphism at nucleotide 46 in the 5′ untranslated region of the factor XII gene protects from development of acute coronary syndrome. Br J Haematol 2001; 115: 1007-1009
    CrossrefPubMedGoogle Scholar
  • 26 Endler G, Exner M, Mannhalter C, Meier S, Ruzicka K, Handler S, Panzer S, Wagner O, Quehenberger P. A common C→T polymorphism at nt 46 in the promoter region of coagulation factor XII is associated with decreased factor XII activity. Thromb Res 2001; 101: 255-260
    CrossrefPubMedGoogle Scholar
  • 27 Bach J, Endler G, Winkelmann BR, Boehm BO, Maerz W, Mannhalter C, Hellstern P. Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk. J Thromb Haemost 2008; 6: 291-296
    CrossrefPubMedGoogle Scholar
  • 28 Bohdanowicz-Pawlak A, Szymczak A, Waszczuk E, Bolanowski M, Bednarek-Tupikowska G. Subclinical Cushing’s syndrome in adrenal incidentalomas – possible metabolic consequences. Endokrynol Pol 2013; 64: 186-191
    PubMedGoogle Scholar
  • 29 Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, Hamaskai N, Niho Y. A common Genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91: 2010-2014
    CrossrefPubMedGoogle Scholar
  • 30 Tirado I, Soria JM, Mateo J, Oliver A, Souto JC, Santamaria A, Felices R, Borrell M, Fontcuberta J. Association after linkage analysis indicates that homozygosity for the 46C→T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis. Thromb Haemost 2004; 91: 899-904
    PubMedGoogle Scholar
  • 31 Kohler HP, Futers TS, Grant PJ. FXII (46C→T) polymorphism and in vivo generation of FXII activity – gene frequencies and relationship in patients with coronary artery disease. Thromb Haemost 1999; 8: 745-747
    PubMedGoogle Scholar
  • 32 Girolami A, Scarparo P, Vettore S. The association of mild FXII deficiency with myocardial infarction and venous thrombosis is completely unjustified. J Thromb Thrombolysis 2009; 27: 454-455
    CrossrefPubMedGoogle Scholar
  • 33 Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F. The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. J Thromb Thrombolysis 2004; 17: 139-143
    CrossrefPubMedGoogle Scholar
  • 34 Terzolo M, Allasino B, Bosio S, Brusa E, Daffara F, Ventura M, Aroasio E, Sacchetto G, Reimondo G, Angeli A, Camaschella C. Hyperhomocysteinemia in patients with Cushing’s syndrome. J Clin Endocrinol Metab 2004; 89: 3745-3751
    CrossrefPubMedGoogle Scholar
  • 35 Światkowska-Stodulska R, Kaniuka-Jakubowska S, Wiśniewski P, Skibowska-Bielińska A, Sworczak K. The estimation of selected endogenous anticoagulation system parameters in patients with subclinical Cushing’s syndrome. Eur J Endocrinol 2011; 165: 865-871
    CrossrefPubMedGoogle Scholar